No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.

M van VugtShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by M van Vugt in
Current site
Google Scholar
PubMed
Close
,
F EzzetShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by F Ezzet in
Current site
Google Scholar
PubMed
Close
,
F NostenShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by F Nosten in
Current site
Google Scholar
PubMed
Close
,
I GathmannShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by I Gathmann in
Current site
Google Scholar
PubMed
Close
,
P WilairatanaShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by P Wilairatana in
Current site
Google Scholar
PubMed
Close
,
S LooareesuwanShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by S Looareesuwan in
Current site
Google Scholar
PubMed
Close
, and
N J WhiteShoklo Malaria Research Unit, Mae Sod, Thailand.

Search for other papers by N J White in
Current site
Google Scholar
PubMed
Close
Restricted access

Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

Save